PUF Ventures Inc. (CSE:PUF, Frankfurt:PU3, OTCPK:PUFXF) (“PUF” or the “Company”), an advanced Access to Cannabis for Medical Purposes Regulations (“ACMPR”) license applicant, is pleased to congratulate the team at Cannvas MedTech Inc. (CSE:MTEC) (Frankfurt:3CM) for the launch of Cannvas.Me, an unbiased educational resource for medicinal and adult-use cannabis users which is now available online at http://Cannvas.Me.

In September 2017, PUF announced the spin-off of certain assets to form a company which subsequently became Cannvas MedTech.


“I would like to congratulate Shawn Moniz and Steve Loutskou of Cannvas MedTech on the launch of their first commercial online platform,” said Derek Ivany, President and CEO of PUF Ventures. “We are on the eve of legalization and the cannabis space in Canada is in need of information and education that people can trust and rely on. Using advanced technology, Shawn and Steve have built an impressive web portal that delivers physician vetted content for both medicinal and recreational cannabis users. I wish Shawn and Steve and the rest of their team the very best on a successful launch and continued growth of their remarkable web portal.”

Cannvas MedTech designs and builds customer-centric solutions that enable partners and clients to harness the power of data to truly understand their customers, industry, and key business drivers. The PUF spinout company has established itself as a leading business technology company in the cannabis health sciences space and began trading on the Canadian Stock Exchange with the symbol MTEC on July 3, 2018, and on the Frankfurt Exchange with the symbol 3CM on July 18, 2018.

Its first offering, Cannvas.Me, is a scalable, patient-centric life sciences learning platform for the global medical cannabis industry. Patients, consumers, medical practitioner and licensed producers, will use the Cannvas.Me platform for global interaction and cannabis education.

About Cannvas MedTech Inc.

Cannvas MedTech is a leading business technology company in the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers. For additional information: www.cannvasmedtech.com.

About PUF Ventures Inc.

PUF Ventures Inc. is a growth oriented and diversified company focused on the international cannabis industry. It has ownership in several cannabis companies including AAA Heidelberg and Propagation Services Canada in Canada, a large-scale greenhouse project in Australia and actively pursuing other opportunities within the cannabis industry. PUF has an option to purchase 100% of AAA Heidelberg Inc., an advanced applicant for an ACMPR license. For more information please visit: www.puf.ca.

ON BEHALF OF THE BOARD OF DIRECTORS

Derek Ivany
President & CEO

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.

Click here to connect with PUF Ventures Inc. (CSE:PUF, Frankfurt:PU3, OTCPK:PUFXF) for an Investor Presentation.

Source: www.newswire.ca

US-based multi-state operators (MSOs) performed well during Q1, but one fund manager believes that hasn’t been reflected in their share prices.

Keep reading... Show less

 Aion Therapeutic Inc. (CSE: AION) (” Aion Therapeutic ” or the ” Company “) announced today that its proprietary and patented combinatorial mushroom preparations AION F7 and AION F8 (collectively, the ” Aion Mushroom Preparations ” or ” Preparations “) showed high efficacy in killing HER2+ breast cancer cells, ER+PR+ breast cancer cells, and triple-negative breast cancer cells by direct cytotoxicity.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) (“Nextleaf”, “OILS”, or the “Company”) , the world’s most innovative cannabis processor, is pleased to announce that its wholly-owned subsidiary Nextleaf Labs Ltd. (“Nextleaf Labs” or “Labs”) has completed an inaugural bulk CBD distillate delivery to a U.S.-listed, Canadian-based global cannabis company. The Company anticipates similar orders on an ongoing basis.

Keep reading... Show less

The Company Will Tap into Southern Glazer’s Established Distribution Network to Bring Quatreau, its CBD-Infused Sparkling Water, to U.S. Retailers

 Canopy Growth Corporation (“Canopy Growth”) (TSX: WEED) (NASDAQ: CGC), a world-leading diversified cannabis, CBD and vaporization device company, today announced Southern Glazer’s Wine & Spirits (“Southern Glazer’s”), the world’s pre-eminent distributor of beverage alcohol, as the distribution partner for its U.S. portfolio of CBD-infused beverages. This partnership announcement follows the recent launch of Quatreau Canopy’s first line of CBD-infused beverages sold in the U.S market.

Keep reading... Show less

 Canbud Distribution Corporation (CSE: CBDX) (FSE: CD0) (“Canbud” or the “Corporation”) announces its subsidiary Empathy Plant Co. has completed the full development of its vegan multivitamin formula exclusively for women.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7448/81051_95aa98db045cb95d_001.jpg
Unique Vegan Women’s Multi-Vitamin with 100% Compostable Packaging

Keep reading... Show less